



Clinical Research Article

Korean J Anesthesiol 2021;74(3):242-253

<https://doi.org/10.4097/kja.20296>

pISSN 2005-6419 • eISSN 2005-7563

Received: June 6, 2020

Revised: August 17, 2020

Accepted: August 23, 2020

Corresponding author:

Gyu-Sam Hwang, M.D., Ph.D.

Department of Anesthesiology and Pain Medicine, Laboratory for Cardiovascular Dynamics, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea

Tel: +82-2-3010-3868

Fax: +82-2-470-1363

Email: kshwang@amc.seoul.kr

ORCID: <https://orcid.org/0000-0002-3627-1107>

Preoperative high-sensitivity troponin I and B-type natriuretic peptide, alone and in combination, for risk stratification of mortality after liver transplantation

Young-Jin Moon, Hye-Mee Kwon, Kyeo-Woon Jung, Kyoung-Sun Kim, Won-Jung Shin, In-Gu Jun, Jun-Gol Song, Gyu-Sam Hwang

Department of Anesthesiology and Pain Medicine, Laboratory for Cardiovascular Dynamics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Background: Given the severe shortage of donor liver grafts, coupled with growing proportion of cardiovascular death after liver transplantation (LT), precise cardiovascular risk assessment is pivotal for selecting recipients who gain the greatest survival benefit from LT surgery. We aimed to determine the prognostic value of pre-LT combined measurement of B-type natriuretic peptide (BNP) and high-sensitivity troponin I (hsTnI) in predicting early post-LT mortality.

Methods: We retrospectively evaluated 2,490 consecutive adult LT patients between 2010 and 2018. Cut-off values of BNP and hsTnI for predicting post-LT 90-day mortality were calculated. According to the derived cut-off values of two cardiac biomarkers, alone and in combination, adjusted hazard ratios (aHR) of post-LT 90-day mortality were determined using multivariate Cox regression analysis.

Results: Mortality rate after 90 days was 2.9% (72/2,490). Rounded cut-off values for post-LT 90-day mortality were 400 pg/ml for BNP (aHR 2.02 [1.15, 3.52], $P = 0.014$) and 60 ng/L for hsTnI (aHR 2.65 [1.48, 4.74], $P = 0.001$), respectively. Among 273 patients with BNP ≥ 400 pg/ml, 50.9% of patients were further stratified into having hsTnI ≥ 60 ng/L. Combined use of pre-LT cardiac biomarkers predicted post-LT 90-day mortality rate; both non-elevated: 1.0% (21/2,084), either one is elevated: 9.0% (24/267), and both elevated: 19.4% (27/139, log-rank $P < 0.001$; aHR vs non-elevated 4.23 [1.98, 9.03], $P < 0.001$).

Conclusions: Concomitant elevation of both cardiac biomarkers posed significantly higher risk of 90-day mortality after LT. Pre-LT assessment cardiac strain and myocardial injury, represented by BNP and hsTnI values, would contribute to prioritization of LT candidates and help administer target therapies that could modify early mortality.

Keywords: B-type natriuretic peptide; Liver transplantation; Mortality; Postoperative complication; Risk assessment; Troponin-I.

Introduction

Given the severe shortage of donor liver grafts, the role of precise preoperative risk stratification is crucial to select a recipient who gains the greatest survival benefit from liver transplantation (LT) surgery. With improved surgical techniques and anesthetic management, cardiovascular disease is now the leading cause of early mortality following

© The Korean Society of Anesthesiologists, 2021

© This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

LT [1]. As a consequence, there is an increasing need for exact tools to evaluate cardiovascular risk in LT candidates [2,3]. However, the current model for end-stage liver disease (MELD) scoring system does not reflect any cardiovascular markers in its calculation. Since the era of MELD scores started in 2002, it allowed more objective prediction of 90-day mortality and improved prioritization of LT candidates [4], but it has remained barely unchanged for the last 20 years despite the ongoing need for revision [5]. Moreover, current noninvasive tests, such as dobutamine stress echocardiography and myocardial perfusion scan, which are mainly for detecting subclinical coronary and myocardial disease, do not have satisfactory performance in predicting postoperative outcomes [6].

Cardiac biomarkers, including B-type natriuretic peptide (BNP) and cardiac troponins, have been recognized for their powerful prognostic ability [7–9]. Guidelines on preoperative cardiovascular risk assessment recommend measuring BNP and cardiac troponin in patients scheduled for high-risk non-cardiac surgeries [10,11]. Troponin and BNP are reported to be correlated with severity liver disease [12], and a few studies have demonstrated the relevance of pre- and intraoperative elevated levels of these biomarkers in predicting LT outcome. Nevertheless, comprehensive combined interpretation of these two biomarkers and optimal cut-off values for LT candidates are still not established. For example, several studies employ just the 99th percentile upper reference limit (URL) of high-sensitivity troponin I (hsTnI), which has been used for healthy reference population [13,14], without consideration of particular cardiovascular characteristics such as a hyperdynamic circulation and the severity of illness in LT candidates.

Thus, we conducted this study to investigate whether elevation of cardiac strain indicated by a high BNP and accompanying subclinical myocardial injury assessed by hsTnI predict early mortality after LT. If so, the combined use of two cardiac biomarkers would help to improve preoperative risk stratification of LT candidates.

The objectives of the current study are (1) to determine any association between preoperative cardiac troponin and BNP in LT candidates, and (2) to define preoperative threshold of each biomarker that could predict short-term (90-day) mortality to assess the prognostic usefulness of these biomarkers, alone and in combination, in LT recipients.

Materials and Methods

Study Population

This retrospective study was approved by the Institutional Re-

view Board of Asan Medical Center (2019-0824). A total of 2,949 consecutive patients who underwent adult LT from January 2010 to January 2018 were reviewed. Of these, we excluded patients whose preoperative troponin I and BNP were not measured within a week before LT (n = 374) and those who underwent re-transplantation or multi-organ transplantation (n = 85). We included patients with a previous history of coronary artery disease (CAD), treated with percutaneous coronary intervention or coronary artery bypass surgery, to determine whether preoperative ischemic heart disease is a prerequisite for hsTnI release and portends a poorer survival rate during the early post-LT period.

Measurement of Troponin I and brain natriuretic peptide

Both cardiac markers, hsTnI and BNP, were routinely measured preoperatively as part of the institution's routine protocol since 2010. Cardiac hsTnI was measured using ADVIA Centaur® XP TnI-Ultra (Siemens Healthcare Diagnostics, USA; the 99th percentile URL = 40 ng/L, lower limit = 6 ng/L). Plasma level of BNP was measured using ADVIA Centaur® CP Immunoassay System (Siemens Healthcare Diagnostics, USA). We only approved cardiac biomarkers that were measured within a week before LT or just before induction of anesthesia for LT. If there were multiple measurements of cardiac biomarkers, the latest sample before LT was used for analysis.

Data collection and definition of outcomes

Data collection was performed using a fully computerized Asan Medical Center research information system (ABLE, Asan Biomedical Research) after approval from the local research ethics committee (protocol number 2019-0881), which waived the requirement for written informed consent. This included patient demographics, medical history, MELD score of liver cirrhosis severity, laboratory variables, comorbidities of liver cirrhosis, and mortality. Patient survival time was defined as the number of days between the day of surgery starting in January 2010 and ending on March 31, 2018 or the date of death (completed). Mortality data were obtained from patients' electronic medical records and the Asan LT registry, which is regularly updated by the Asan Organ Transplantation Center. The primary end point was the cumulative 90-day all-cause mortality and secondary outcomes included cumulative overall mortality during the entire follow-up period.

Statistical analysis

Variables are expressed as numbers (percentages), mean ±

standard deviation, or median (Q1, Q3) as appropriate. Analyses between groups were performed using Student's *t*-test, Mann-Whitney *U* test, analysis of variance, or Kruskal-Wallis test for continuous variables and χ^2 test or Fisher's exact test for categorical variables, as appropriate. Distribution of BNP and hsTnI were evaluated with a histogram and a density plot according to patient survival. To assess the relationship between preoperative hsTnI and BNP values, they were log-transformed and depicted on a scatter plot and analysis of covariance was performed to evaluate the association between the two cardiac biomarkers and patient mortality.

Optimal cut-off points of each cardiac biomarker for 90-day mortality and overall mortality were calculated using the 'maxstat' package of R (version 3.3.1, R foundation for statistical Computing, Austria). Briefly, using maximally selected rank statistics, the prognostic cut-off point was determined by evaluating every possible cut-off point, classifying all patients into two groups according to their level, and selecting the most discriminating threshold for death, corresponding to the minimum *P* value according to the log-rank test [15,16]. The main difference of maximally selected rank statistics from classic receiver operating characteristic curve analysis is that there is no need to change a time-dependent endpoint (survival) into a classification variable [16]. In receiver operating curve analysis, investigators have to transform the time-dependent end point (survival) into a binary end point that is clinically relevant (e.g., survival at certain time point). Using the 'maxstat' package of R, maximally selected rank analysis for finding cut-off values that discriminate survival curves (time-dependent endpoint) can be done easily. Following this analysis, patients were dichotomized using these cut-off values and then patients were further divided into three groups using a combination of both cut-off values: both decreased, either one elevated, and both elevated. The three groups were evaluated by Kaplan-Meier analysis with log-rank test (Mantel-Cox), and its independent prognostic role was evaluated with the Cox regression model. The derived hazard ratios (HR) were adjusted by established risk factors reported from previous studies. Those factors included age [17], sex [18], deceased brain death donor or living donor LT [19,20], hepatic encephalopathy [21], massive transfusion (intraoperative transfusion of packed red blood cells > 10 units) [22], renal replacement therapy [23], MELD score, and C-reactive protein [24]. Donor age and height, cold/warm ischemic time, and graft-to-recipient body weight ratio were also included as covariates for donor risk factors [17,25–27]. We further performed a subgroup analysis by MELD score of 15. Kaplan-Meier curves were further stratified using a MELD score of 15 to observe the effect of liver disease severity.

Cubic spline interpolation was performed to represent the continuous changes in risk of 90-day all-cause death according to BNP and hsTnI values; three knots were considered. The BNP for which hazard ratio was equal to unity was chosen at the optimal cut-off value of BNP.

P values < 0.05 were considered statistically significant. All statistical analyses were performed using R software version 3.3.1.

Results

Baseline characteristics

Of the 2,490 included patients of aged 20–78 years, 2,122 (85.2%) underwent living donor and 368 (14.8%) underwent deceased brain death donor LT (Table 1). The patient population consisted of 1,843 (74.0%) men and 647 (26%) women, of median age 54 years (48–59) and a median MELD score of 14 (9–24). The primary causes of liver disease were hepatitis B or C virus-related liver cirrhosis (LC, 62.9%), alcoholic LC (21.8%), and others (15.3%).

During a median follow-up of 2.9 years (1.3, 4.9), 221 (8.9%) patients died after LT, including 72 (2.9%) who died during the first 90 days. Cardiovascular-related death comprised 24.9% (55/221) and 30.6% (22/72) of overall and 90-day mortality causes, respectively. Baseline characteristics of all patients are depicted in Table 1.

Preoperative BNP concentrations

The BNP histogram of the 2,490 enrolled patients is shown in Fig. 1. The median level of preoperative BNP was 80 pg/ml (39–178) and 1,044 (42%) had BNP > 100 pg/ml [28,29]. Patients who died within 90 days had significantly higher BNP values compared with those who survived for at least 90 days (median, 455.5 vs. 77.0 pg/ml, *P* < 0.001). With maximally selected rank statistic for the prediction of 90-day and overall mortality during the entire follow-up period, best cut-off values of BNP were 325 pg/ml and 442 pg/ml, respectively; therefore, we rounded them off to 400 pg/ml, which is an already well-known cut-off value associated with mortality risk [30]. When dichotomized with these cut-off values, patients with BNP ≥ 400 pg/ml (*n* = 273, 11%) had higher MELD scores (median, 34 vs. 13, *P* < 0.001). The 90-day mortality rate differed using a cut-off value of BNP of 400 pg/ml (1.6% vs. 13.6%, *P* < 0.001), with corresponding crude HR of 9.14 (95% CI, 5.75, 14.50, *P* < 0.001) and adjusted HR of 2.02 (95% CI, 1.15, 3.52, *P* = 0.014, Tables 1 and 2).

Table 1. Demographics according to the Cut-off Values of Cardiac Biomarkers

	Baseline BNP level (pg/ml)		Baseline hsTnI level (ng/L)		P value	Total (n = 2,490)
	< 400 (n = 2,217)	≥ 400 (n = 273)	< 60 (n = 2,218)	≥ 60 (n = 272)		
Demographic data						
Age (yr)	54.0 (48.0, 59.0)	55.0 (48.0, 61.0)	54.0 (48.0, 59.0)	55.0 (48.0, 61.0)	0.021	54.0 (48.0, 59.0)
Sex (M)	1670 (75.3)	173 (63.4)	1672 (75.4)	171 (62.9)	< 0.001	1843 (74.0)
Body mass index (kg/m ²)	23.8 (21.6, 26.0)	22.8 (20.3, 25.5)	23.7 (21.5, 26.0)	23.5 (21.2, 26.1)	0.449	23.7 (21.5, 26.0)
MELD score	13.0 (9.0, 21.0)	34.0 (26.0, 41.0)	13.0 (9.0, 21.0)	34.0 (27.0, 41.0)	< 0.001	14.0 (9.0, 24.0)
Underlying disease						
Diabetes mellitus	505 (22.8)	67 (24.5)	514 (23.2)	58 (21.3)	0.543	572 (23.0)
Hypertension	382 (17.2)	39 (14.3)	373 (16.8)	48 (17.6)	0.796	421 (16.9)
Chronic kidney disease	14 (0.6)	3 (1.1)	13 (0.6)	4 (1.5)	0.200	17 (0.7)
Coronary artery disease	26 (1.2)	3 (1.1)	23 (1.0)	6 (2.2)	0.163	29 (1.2)
Cerebrovascular disease	13 (0.6)	0 (0.0)	13 (0.6)	0 (0.0)	0.412	13 (0.5)
Cause for liver transplantation					< 0.001	
Hepatitis B virus-related LC	1303 (58.8)	87 (31.9)	1269 (57.2)	121 (44.5)		1390 (55.8)
Hepatitis C virus-related LC	158 (7.1)	16 (5.9)	156 (7.0)	18 (6.6)		174 (7.0)
Alcoholic LC	433 (19.5)	111 (40.7)	475 (21.4)	69 (25.4)		544 (21.8)
Others	323 (14.6)	59 (21.6)	318 (14.3)	64 (23.5)		382 (15.3)
Donor and intraoperative variables						
Deceased brain death donor liver transplant	240 (10.8)	128 (46.9)	233 (10.5)	135 (49.6)	< 0.001	368 (14.8)
Donor age (yr)	28.0 (22.0, 35.0)	34.0 (26.0, 47.0)	28.0 (22.0, 35.0)	35.0 (27.0, 46.0)	< 0.001	28.0 (22.0, 36.0)
Donor height (cm)	170.3 (163.1, 175.4)	169.0 (160.0, 175.0)	170.2 (163.0, 175.4)	170.0 (162.2, 175.0)	0.113	170.2 (163.0, 175.3)
Graft-to-recipient weight ratio	1.1 (1.0, 1.4)	1.5 (1.1, 2.2)	1.1 (1.0, 1.4)	1.5 (1.1, 2.3)	< 0.001	1.1 (1.0, 1.4)
Total ischemic time (min)	129.0 (109.0, 156.0)	175.0 (117.0, 321.0)	129.0 (109.0, 155.0)	181.5 (120.0, 324.5)	< 0.001	130.0 (110.0, 159.0)
Massive transfusion	474 (21.4)	108 (39.6)	474 (21.4)	108 (39.7)	< 0.001	582 (23.4)
Laboratory variables						
Hemoglobin (g/dl)	10.6 (9.1, 12.4)	8.4 (7.6, 9.4)	10.6 (9.0, 12.4)	8.9 (8.0, 10.0)	< 0.001	10.4 (8.8, 12.3)
Creatinine (mg/dl)	0.8 (0.6, 0.9)	1.3 (0.8, 2.1)	0.8 (0.6, 0.9)	1.2 (0.8, 2.1)	< 0.001	0.8 (0.6, 1.0)
Total bilirubin (mg/dl)	1.8 (0.9, 5.4)	15.7 (4.5, 28.5)	1.8 (0.9, 5.2)	19.4 (5.8, 30.5)	< 0.001	2.0 (1.0, 8.5)
Prothrombin time (INR)	24.0 (16.0, 38.0)	27.0 (16.0, 51.0)	23.0 (16.0, 37.0)	38.0 (21.0, 83.0)	< 0.001	24.0 (16.0, 38.0)
C-reactive protein (mg/L)	0.3 (0.1, 0.9)	1.4 (0.6, 2.9)	0.3 (0.1, 0.9)	1.3 (0.6, 2.8)	< 0.001	0.3 (0.1, 1.0)
Comorbidities						
Varix bleeding	589 (26.6)	64 (23.4)	601 (27.1)	52 (19.1)	0.006	653 (26.2)
Intractable ascites	576 (26.0)	145 (53.1)	595 (26.8)	126 (46.3)	< 0.001	721 (29.0)
Hepatic encephalopathy	325 (14.7)	145 (53.1)	290 (13.1)	180 (66.2)	< 0.001	470 (18.9)

Values are presented as numbers (%), mean ± SD, or median (Q1, Q3). Massive transfusion was defined as > 10 units of red blood cell transfusion. BNP: B-type natriuretic peptide, hsTnI: high-sensitivity troponin I, MELD: model for end-stage liver disease, LC: liver cirrhosis.




Fig. 1. Histogram and accompanying density plot of baseline BNP and hsTnI. Note the difference in distributions of BNP and hsTnI according to the survival. BNP: B-type natriuretic peptide, hsTnI: high-sensitivity troponin I, POD: postoperative day.

Preoperative hsTnI concentrations

The frequency histogram of the hsTnI of the 2,490 enrolled patients is shown in Fig. 1. The median level of preoperative hsTnI was 6 ng/L (6, 160). A total of 1,463 (58.8%) patients showed normal hsTnI concentration of 6 ng/L, which is the lowest detectable value in the current study; therefore, 1,027 (41.2%) patients' hsTnI exceeded 6 ng/L. Of 2,490 patients enrolled, 683 patients (27.4%) had levels between 7 ng/L and the 99th percentile URL (= 40 ng/L), 344 patients (13.8%) exceeded the 99th percentile URL (> 40 ng/L), and 272 (10.9%) had 1.5 times (> 60 ng/L), 133 (5.3%) had 5 times (> 200 ng/L), 84 (3.4%) had 10 times (> 400 ng/L), and 28 (1.1%) had 30 times the 99th percentile URL (> 1,200 ng/L), respectively.

Non-survivors within 90 days had significantly higher hsTnI values compared with survivors (median, 95 vs. 6 ng/L, $P < 0.001$). The best cut-off values of hsTnI for patients who died within 90 days and those who died during the entire follow-up period were 65 ng/L and 62 ng/L, respectively. Although the primary end-point of the current study is the 90-day mortality, these two cut-off values are very similar; therefore, we rounded them off to 60 ng/L, which is 1.5 times 99th percentile URL. When dichotomized with these cut-off values, patients with hsTnI ≥ 60 ng/L ($n = 272$, 10.9%) had higher MELD scores (median, 34 vs. 13, $P < 0.001$). The 90-day mortality rates according to a cut-off value of hsTnI of 60 ng/L were 1.4% and 15.1% ($P < 0.001$), with corresponding crude and adjusted HRs of 11.65 (7.31, 18.58; $P < 0.001$) and 2.65 (1.48, 4.74; $P = 0.001$), respectively (Tables 1 and 2).

Table 2. Hazard Ratio for 90-day Mortality according to the Level of Baseline Cardiac Biomarkers Alone and in Combination

	Event (%)	Crude HR (95% CI)	P value	Adjusted HR (95% CI)	P value
Baseline BNP					
As continuous variable (log-transformed)	NA	6.50 (4.55, 9.28)	< 0.001	2.10 (1.32, 3.34)	0.002
According to the Threshold Analysis of BNP (pg/ml)					
< 400	35/2217 (1.6)		Reference		
≥ 400	37/273 (13.6)	9.14 (5.75, 14.50)	< 0.001	2.02 (1.15, 3.52)	0.014
Baseline hsTnI					
As continuous variable (log-transformed)	NA	3.80 (3.08, 4.69)	< 0.001	2.27 (1.64, 3.13)	< 0.001
According to the Threshold Analysis of hsTnI (ng/L)					
< 60	31/2218 (1.4)		Reference		
≥ 60	41/272 (15.1)	11.65 (7.31, 18.58)	< 0.001	2.65 (1.48, 4.74)	0.001
Combination of BNP and hsTnI					
According to the Threshold Analysis of BNP (pg/mL) and hsTnI (ng/L)					
BNP < 400, hsTnI < 60	21/2084 (1.0)		Reference		
BNP ≥ 400, hsTnI < 60	10/134 (7.5)	7.69 (3.62, 16.33)	< 0.001	2.52 (1.07, 5.89)	0.033
BNP < 400, hsTnI ≥ 60	14/133 (10.5)	11.14 (5.66, 21.90)	< 0.001	3.30 (1.49, 7.31)	0.003
BNP ≥ 400, hsTnI ≥ 60	27/139 (19.4)	21.19 (11.98, 37.48)	< 0.001	4.23 (1.98, 9.03)	< 0.001

Values are presented as numbers (%) or hazard ratio (95% CI). The Cox regression models were adjusted using age, sex, deceased donor liver transplantation, hepatic encephalopathy, pretransplant vasopressor use, massive transfusion (> 10 units of red blood cell transfusion), renal replacement therapy, model for end-stage liver disease score, C-reactive protein, donor age, donor height, total ischemic time, and graft-to-recipient weight ratio. HR: hazard ratio, BNP: B-type natriuretic peptide, hsTnI: high-sensitivity troponin I.

Relationship between hsTnI and BNP

There was a significant correlation between BNP and hsTnI ($r = 0.567$, $P < 0.001$) in all patients, and non-survivors showed more correlation between BNP and hsTnI compared with survivors ($r = 0.686$ vs. 0.472 , interaction $P < 0.001$, Fig. 2). The proportion of patients with hsTnI plasma level ≥ 60 ng/L was 50.9% in the subset of patients with BNP ≥ 400 pg/ml and 6.0% in the subset with a BNP < 400 pg/ml ($P < 0.001$).

Patients with history of coronary artery disease

Patients with a previous history of CAD ($n = 29$, 1.2%) had slightly higher baseline hsTnI concentration [15 ng/L (6–47) vs. 6 ng/L (6–16), $P = 0.004$], but the proportion of patients with hsTnI ≥ 40 ng/L (27.6% vs. 13.9%, $P = 0.063$) was not statistically different compared with the patients with no known history of CAD. Additionally, baseline BNP concentration in patients with CAD was not significantly different compared with those without a history of CAD [73 pg/ml (52, 198) vs. 80 pg/ml (39, 178), $P = 0.901$]. Furthermore, 90-day mortality (3.5% vs. 2.9%, $P = 0.999$) and overall mortality during the entire follow-up period (8.9% vs. 6.9%, $P = 0.961$) were similar.

Mortality according to the BNP and hsTnI cut-off values in combination

Using a combination of two cut-off values: both decreased, either one elevated, or both elevated, three subsets were generated and patients' characteristics in each of them are described in Supplementary Table 1. One hundred and thirty-nine patients (5.6%) were in the subset with both elevated, 267 (10.7%) were in the subset with either one elevated, and 2,084 (83.7%) were in the subset with both decreased. The subset with both elevated (BNP ≥ 400 pg/ml and hsTnI ≥ 60 ng/L) showed higher MELD scores and suffered more severe hepatic comorbidities compared with the subset with both decreased (Supplementary Table 1). They exhibited higher crude and adjusted HRs of 21.19 (11.98, 37.48; $P < 0.001$) and 4.23 (1.98, 9.03; $P < 0.001$), respectively, compared with that with both decreased (Table 2).

Specifically, when patients are dichotomized by liver disease severity using the MELD score, clear separation of Kaplan-Meier survival curves for mortality depending on the particular combination of BNP and hsTnI values was demonstrated. The number of deaths that occurred in the subset with MELD scores ≥ 15 was greater than the number in the subset with MELD scores < 15 (Fig. 3). Importantly, most of the deaths occurred within 1 year in patients with both biomarkers elevated. Among patients with MELD score ≥ 15 , the 90-day mortality rates were 19.9% for pa-




Fig. 2. Scatter plot of baseline BNP and hsTnI showing the different relationship of the two cardiac biomarkers according to the survival (A). The slope of the regression line from deaths is significantly steeper than those from survivors ($r = 0.686$ vs. 0.472 , interaction $P < 0.001$). The stacked bar plot shows the proportion of patients who were stratified into categories according to the cut-off values of baseline BNP and hsTnI (B). Note that the patients with BNP ≥ 400 pg/ml are divided still further into having hsTnI < 60 ng/L and ≥ 60 ng/L in nearly equal proportions. BNP: B-type natriuretic peptide, hsTnI: high-sensitivity troponin I.




Fig. 3. Kaplan-Meier survival curves according to the combinations of baseline BNP and hsTnI. The survival curves are plotted separately in subgroups of MELD score < 15 and ≥ 15 , respectively, which diverge only in subgroup of MELD score ≥ 15 . The 90-day mortality rates and overall mortality rate in MELD score ≥ 15 were 19.9%/36.8% for patients with both cardiac biomarkers elevated, 10.0%/16.3% for those with either one of the cardiac biomarkers elevated, and 1.7%/6.4% for those with both cardiac biomarkers decreased. BNP: B-type natriuretic peptide, hsTnI: high-sensitivity troponin I, MELD: model for end-stage liver disease.

tients with both cardiac biomarkers elevated and 1.7% for those with both cardiac biomarkers decreased. Both cardiac biomarkers showed significant correlations with MELD scores, with more

wide distribution among higher MELD scores (Supplementary Fig. 1). For 1,367 patients with low MELD score (< 15), only 0.2% of the patients showed both BNP and hsTnI elevated, whereas




Fig. 4. Hazard ratio curve with splines for 90-day mortality according to the baseline BNP and hsTnI. The model was adjusted for age, sex, deceased donor liver transplantation, hepatic encephalopathy, massive transfusion (> 10 units of red blood cell transfusion), renal replacement therapy, model for end-stage liver disease score, C-reactive protein, donor age, donor height, total ischemic time, and graft-to-recipient weight ratio. The shaded area represents 95% CIs of the hazard ratio estimates. Increased BNP is associated with increasing trends of hazard ratio. Note that the cut-off value of hsTnI (60 ng/L) significantly separates the hazard ratio among patients with increased BNP above a cut-off value of 400 pg/ml. BNP: B-type natriuretic peptide, hsTnI: high-sensitivity troponin I.

98.2% of them had neither elevated BNP nor elevated hsTnI above the cut-off values.

Restricted cubic spline analysis showing the hazard ratio of 90-day mortality with preoperative BNP on a continuous scale, with BNP 400 pg/ml as the reference value, grouped by a cut-off value for hsTnI of 60 ng/L is shown in Fig. 4.

Discussion

In the present study, we provide evidence supporting the feasibility of risk stratification using both cardiac biomarkers (BNP and hsTnI) concomitantly before LT surgery. The early 90-day mortality rate is clearly stratified into broad levels according to the combinations of preoperative BNP and hsTnI values, particularly among those with advanced liver cirrhosis with high MELD scores. The main findings of the present study were: (1) There was a significant correlation between BNP and hsTnI ($r = 0.567$, $P < 0.001$) in LT candidates; non-survivors, in particular, showed a stronger correlation, which implies that more myocardial injury might be imposed on elevated cardiac strain when compared with survivors ($r = 0.686$ vs. 0.472 , interaction $P < 0.001$). (2) The best

cut-off values of BNP and hsTnI for mortality prediction were 400 pg/ml and 60 ng/L (i.e., 1.5 times 99th percentile URL), respectively. (3) A half of those who had BNP ≥ 400 pg/ml are further stratified into having hsTnI ≥ 60 ng/L. (4) Using these cut-off values, patients with elevation of both BNP and hsTnI had a markedly greater risk of early 90-day mortality (19.4%) than those with elevation of either (9.0%) or neither (1.0%) of these 2 biomarkers; this result was profound in patients with MELD score ≥ 15 .

In the present study, there was a significant correlation between BNP and hsTnI and this correlation was stronger in non-survivors. Approximately one half of patients (50.9%) with BNP ≥ 400 pg/ml had elevation of hsTnI ≥ 60 ng/L; in contrast, only 6% of patients with BNP < 400 pg/ml had hsTnI ≥ 60 ng/L. These findings suggest that release of hsTnI and BNP might be associated with each other and hsTnI release is activated partly by the increased cardiac strain (reflected by the high BNP) in response to various pathophysiological changes and/or stimuli of advanced liver disease, although the exact mechanism is unclear. It has been known that the physiological stimuli for myocardial production of BNP are an increase in preload and afterload and possibly myocardial ischemia [31,32]; further study will be needed to clarify their role in LT candidates. Indeed, 5.6% patients with both elevated BNP (≥ 400 pg/ml) and hsTnI (≥ 60 ng/L) showed higher MELD scores and suffered more severe comorbidities of advanced liver disease, such as renal replacement therapy, hepatic encephalopathy, and spontaneous bacterial peritonitis, compared with those with both biomarkers decreased (Supplementary Table 1).

We found that the effect of elevation of both cardiac biomarkers was more pronounced among patients with advanced cirrhosis, that is, those with a MELD score ≥ 15 . Among patients with a low MELD score, the proportion of elevation of both BNP and hsTnI was small and did not make any difference in mortality rate. When coupled with high MELD score ≥ 15 , the 90-day mortality rate of patients with concomitantly elevated cardiac biomarkers was over 10 times higher than that of patients with normal cardiac biomarkers (19.9% vs. 1.7%). This implies that the risk stratification using the combination of those cardiac biomarkers is more effective in more advanced end-stage liver disease patients. It is well known that LT is one of the high-risk non-cardiac surgical procedures, involving massive hemorrhage and inferior vena cava clamping. In addition, dynamic circulation, loss of systemic vascular resistance, need for higher cardiac output, and low hemoglobin, all features of severe end-stage liver disease patients, might cause biomarker elevation. And it is often difficult to maintain the vital signs stable without maximized volume resuscitation, which can result in cardiac strain. All those possible causes for pre-LT cardiac biomarker elevation are more pro-

nounced in severe end-state liver disease state, which is well reflected by the higher MELD score. For 1,367 patients with low MELD score (< 15), our data showed that only 0.2% of the patients had elevated levels of both BNP and hsTnI, whereas 98.2% of them had neither elevated BNP nor elevated hsTnI above the cut-off values. Therefore, the clinical practice of measuring cardiac biomarkers in those with higher MELD score, which might go unnoticed without monitoring, is clearly recommended based on the current study results.

Circulating BNP, which is secreted into the circulation in response to increased cardiac wall stress, has been widely used in cardiology as a prognostic and diagnostic biomarker. Additionally, multiple studies have demonstrated that elevated preoperative BNP concentrations are independent predictors of perioperative cardiovascular mortality and morbidity [33,34]. Nevertheless, optimal data are still not available for LT surgery and only a few studies with small cohorts attempted to specify the cut-off values. It has been reported that the cut-off value of pre-LT BNP for predicting 180-day mortality was 155 pg/ml ($n = 207$) [35]. Another study ($n = 104$) demonstrated a BNP level of 100 pg/ml as a cut-off value for predicting early allograft dysfunction [29]. On the other hand, in the 30,487 patients' data from the Vanderbilt University Medical Center electronic health record, the risk of death was similar regardless of whether patients had heart failure or not when the BNP level was sufficiently high. Namely, a BNP level of 400 pg/ml was associated with a three-year risk of death of 21% (95% CI, 20%, 23%) in patients with heart failure and 19% (95% CI, 17%, 20%) in those without [30]. In the present study, with a large LT cohort ($n = 2,490$), the statistically derived optimal cut-off value for the prediction of mortality was also close to 400 pg/ml (325 pg/ml for 90-day mortality and 442 pg/ml for overall mortality during the follow-up period).

Elevated cardiac troponin I levels have been traditionally associated with myocyte necrosis and myocardial infarction. With the development of high-sensitivity assay, it is now possible to detect myocardial injury at an earlier stage. We found that 344 patients (13.8%) exceeded the 99th percentile URL. However, the reference ranges of 99th percentile URL used for diagnosis of myocardial injury in a healthy population may not have equal predictive value for overall early mortality in LT surgery patients [36]. Hitherto, there are no known reference values for this atypical sub-population. In the current study, we provide the best cut-off value of 60 ng/L in LT candidates, which is 1.5 times the 99th percentile URL, and 10.8% of patients exceeded this cut-off value preoperatively.

With rising prevalence of CAD in LT candidates, patients with a previous history of percutaneous coronary intervention or coro-

nary artery bypass surgery are also increasing. In the current study, such patients showed slightly higher baseline hsTnI concentration, but the proportion of patients exceeding the 99th percentile URL and 90-day mortality was not statistically different from those without a history of treatment of ischemic heart disease. We assume that the elevation of cardiac biomarkers, especially troponin, may be more related to type II myocardial infarction from supply/demand mismatch than type I classical myocardial infarction caused by plaque rupture of coronary arteries. This finding suggests that measurement of hsTnI and BNP before LT might be more important than the history of CAD itself.

Our study has several limitations. First, with its retrospective design, which may have selection bias, this study included a heterogeneous group of patients, which may have affected biomarker results and transplant outcomes. However, our current study cohort was large and included consecutive patients who had hsTnI and BNP measurement during routine preoperative and postoperative workups and we provided multivariable adjusted HR. Nevertheless, prospective randomized control studies are needed to validate our results. Second, we evaluated the cardiac biomarkers only within a week before LT. Considering the frequent incidence of hemodynamic instability in LT candidates, a kinetic analysis of serial cardiac biomarker levels would be more informative. Because of the necessity to exercise caution in drawing conclusions from a single study, future studies on the serial analysis of perioperative cardiac biomarkers are warranted. Third, our data were based on the characteristics of patients from a single, large-volume center. Studies including multicenter records that include patients of different ethnicities and backgrounds are therefore needed. Fourth, we do not include data on frailty. Because the field of frailty has only recently been highlighted, our data, which include almost 10 years of consecutive LT, could not cover those functional aspects of LT recipients. However, although there is a rapidly growing body of evidence supporting the association between frailty and harmful outcome after LT [37,38], the consensus on its definition, tools for assessment, and implication for transplant seems not to be established yet [39]. Fifth, our study evaluated cardiac biomarkers only measured within a week before transplant. Most of them are measured just a day before transplant. We used very recent cardiac biomarker values to avoid confounding factors between their measurement and surgery as much as possible. Thus, it may not be reasonable to apply our data result directly into the listing system for cadaveric transplant, where the time course takes weeks and months. Although we demonstrated a clear relationship between hsTnI elevation within a week before transplant and poor outcome, we do not know whether the prognosis difference exists between remote and im-

mediate event(s) of preoperative myocardial injury/strain. As reported in a recent study, there is a possibility that longer duration between cardiac biomarker elevation and surgery might reduce the risk of adverse events [40]. Further studies with more frequent measurement of cardiac biomarkers in liver transplantation recipients should be conducted to discuss whether delaying (or even delisting) of those patients is needed. In addition, appropriate management strategies should be sought to minimize the postoperative risk of adverse outcome.

In conclusion, patients with myocardial injury (high hsTnI) in advanced liver disease with elevated cardiac strain (high BNP) had poorer survival after LT. Therefore, the combined use of preoperative BNP and hsTnI would help to recognize high-risk patients for predicting 90-day mortality after LT, especially in those with advanced MELD score. We recommend the routine monitoring of these two biomarkers in at-risk patients to enhance risk stratification of mortality in LT candidates and help administer target therapies that could modify early mortality.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Author Contributions

Young-Jin Moon (Conceptualization; Data curation; Formal analysis; Visualization; Writing – original draft; Writing – review & editing)

Hye-Mee Kwon (Data curation; Formal analysis; Visualization)

Kyeo-Woon Jung (Data curation)

Kyoung-Sun Kim (Data curation)

Won-Jung Shin (Supervision; Writing – review & editing)

In-Gu Jun (Supervision; Writing – review & editing)

Jun-Gol Song (Supervision; Writing – review & editing)

Gyu-Sam Hwang (Conceptualization; Formal analysis; Methodology; Visualization; Writing – original draft; Writing – review & editing)

Supplementary Materials

Supplementary Table 1. Demographics stratified by combinations of cut-off values of baseline BNP and hsTnI

Supplementary Fig. 1. Scatter plot with linear regression lines showing the distribution of baseline cardiac biomarker values (A: BNP, B: hsTnI) according to the MELD score. Both cardiac biomarkers show significant correlation with the MELD score. BNP:

B-type natriuretic peptide, hsTnI: high-sensitivity troponin I, MELD: model for end-stage liver disease.

ORCID

Young-Jin Moon, <https://orcid.org/0000-0003-3719-1691>

Hye-Mee Kwon, <https://orcid.org/0000-0001-7788-9555>

Kyeo-Woon Jung, <https://orcid.org/0000-0001-6305-6296>

Kyoung-Sun Kim, <https://orcid.org/0000-0002-6643-9177>

Won-Jung Shin, <https://orcid.org/0000-0002-6790-3859>

In-Gu Jun, <https://orcid.org/0000-0002-1225-1793>

Jun-Gol Song, <https://orcid.org/0000-0002-6076-6978>

Gyu-Sam Hwang, <https://orcid.org/0000-0002-3627-1107>

References

1. VanWagner LB, Lapin B, Levitsky J, Wilkins JT, Abecassis MM, Skaro AI, et al. High early cardiovascular mortality after liver transplantation. *Liver Transpl* 2014; 20: 1306-16.
2. Kwon HM, Hwang GS. Cardiovascular dysfunction and liver transplantation. *Korean J Anesthesiol* 2018; 71: 85-91.
3. Moon YJ, Kwon HM, Jung KW, Jeong HW, Park YS, Jun IG, et al. Risk stratification of myocardial injury after liver transplantation in patients with computed tomographic coronary angiography-diagnosed coronary artery disease. *Am J Transplant* 2019; 19: 2053-66.
4. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology* 2003; 124: 91-6.
5. Mahmud N, Goldberg DS. Declining predictive performance of the MELD: Cause for concern or reflection of changes in clinical practice? *Am J Transplant* 2019; 19: 3221-2.
6. VanWagner LB, Harinstein ME, Runo JR, Darling C, Serper M, Hall S, et al. Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: an evaluation of the evidence and consensus recommendations. *Am J Transplant* 2018; 18: 30-42.
7. Weber M, Luchner A, Seeberger M, Mueller C, Liebetrau C, Schlitt A, et al. Incremental value of high-sensitive troponin T in addition to the revised cardiac index for peri-operative risk stratification in non-cardiac surgery. *Eur Heart J* 2013; 34: 853-62.
8. Gillmann HJ, Meinders A, Grohennig A, Larmann J, Bünte C, Calmer S, et al. Perioperative levels and changes of high-sensitivity troponin T are associated with cardiovascular events in vascular surgery patients. *Crit Care Med* 2014; 42: 1498-506.
9. Zimmerman AM, Marwaha J, Nunez H, Harrington D, Hefferman D, Monaghan S, et al. Preoperative myocardial injury as a

- predictor of mortality in emergency general surgery: an analysis using the American College of Surgeons NSQIP Database. *J Am Coll Surg* 2016; 223: 381-6.
10. Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, De Hert S, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). *Eur J Anaesthesiol* 2014; 31: 517-73.
 11. Duceppe E, Parlow J, MacDonald P, Lyons K, McMullen M, Srinathan S, et al. Canadian Cardiovascular Society Guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. *Can J Cardiol* 2017; 33: 17-32.
 12. Zhao J, Li S, Ren L, Guo X, Qi X. Pro-brain natriuretic peptide and troponin t-hypersensitivity levels correlate with the severity of liver dysfunction in liver cirrhosis. *Am J Med Sci* 2017; 354: 131-9.
 13. Park J, Lee SH, Han S, Kim KY, Kim GE, Park M, et al. Elevated High-sensitivity troponin i during living donor liver transplantation is associated with postoperative adverse outcomes. *Transplantation* 2018; 102: e236-44.
 14. Park J, Lee SH, Han S, Jee HS, Lee SK, Choi GS, et al. Preoperative cardiac troponin level is associated with all-cause mortality of liver transplantation recipients. *PLoS One* 2017; 12: e0177838.
 15. Laska E, Meisner M, Wanderling J. A maximally selected test of symmetry about zero. *Stat Med* 2012; 31: 3178-91.
 16. Delgado J, Pereira A, Villamor N, López-Guillermo A, Rozman C. Survival analysis in hematologic malignancies: recommendations for clinicians. *Haematologica* 2014; 99: 1410-20.
 17. Dutkowski P, Oberkofler CE, Slankamenac K, Puhan MA, Schadde E, Müllhaupt B, et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. *Ann Surg* 2011; 254: 745-53.
 18. Sarkar M, Watt KD, Terrault N, Berenguer M. Outcomes in liver transplantation: does sex matter? *J Hepatol* 2015; 62: 946-55.
 19. Hoehn RS, Wilson GC, Wima K, Hohmann SF, Midura EE, Woodle ES, et al. Comparing living donor and deceased donor liver transplantation: a matched national analysis from 2007 to 2012. *Liver Transpl* 2014; 20: 1347-55.
 20. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. *Liver Transpl* 2005; 11: 1265-72.
 21. Morioka D, Egawa H, Kasahara M, Ito T, Haga H, Takada Y, et al. Outcomes of adult-to-adult living donor liver transplantation: a single institution's experience with 335 consecutive cases. *Ann Surg* 2007; 245: 315-25.
 22. Li C, Mi K, Wen TF, Yan LN, Li B, Wei YG, et al. Risk factors and outcomes of massive red blood cell transfusion following living donor liver transplantation. *J Dig Dis* 2012; 13: 161-7.
 23. Iwata H, Mizuno S, Ishikawa E, Tanemura A, Murata Y, Kuriyama N, et al. Negative prognostic impact of renal replacement therapy in adult living-donor liver transplant recipients: preoperative recipient condition and donor factors. *Transplant Proc* 2014; 46: 716-20.
 24. An HJ, Jang JW, Bae SH, Choi JY, Yoon SK, Lee MA, et al. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. *Liver Transpl* 2012; 18: 1406-14.
 25. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. *Am J Transplant* 2006; 6: 783-90.
 26. Rana A, Hardy MA, Halazun KJ, Woodland DC, Ratner LE, Samstein B, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. *Am J Transplant* 2008; 8: 2537-46.
 27. Kiuchi T, Tanaka K, Ito T, Oike F, Ogura Y, Fujimoto Y, et al. Small-for-size graft in living donor liver transplantation: how far should we go? *Liver Transpl* 2003; 9: S29-35.
 28. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med* 2002; 347: 161-7.
 29. Chae MS, Koo JM, Park CS. Predictive role of intraoperative serum brain natriuretic peptide for early allograft dysfunction in living donor liver transplantation. *Ann Transplant* 2016; 21: 538-49.
 30. York MK, Gupta DK, Reynolds CF, Farber-Eger E, Wells QS, Bachmann KN, et al. B-Type Natriuretic Peptide Levels and Mortality in Patients With and Without Heart Failure. *J Am Coll Cardiol* 2018; 71: 2079-88.
 31. Krichevskiy LA, Kozlov IA. Natriuretic peptides in cardiac anesthesia and intensive care. *J Cardiothorac Vasc Anesth* 2019; 33: 1407-19.
 32. Larsen AI, Dickstein K. BNP in acute coronary syndromes: the heart expresses its suffering. *Eur Heart J* 2004; 25: 1284-6.
 33. Karthikeyan G, Moncur RA, Levine O, Heels-Ansdell D, Chan MT, Alonso-Coello P, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measure-

- ment an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. *J Am Coll Cardiol* 2009; 54: 1599-606.
34. Rodseth RN, Lurati Buse GA, Bolliger D, Burkhart CS, Cuthbertson BH, Gibson SC, et al. The predictive ability of pre-operative B-type natriuretic peptide in vascular patients for major adverse cardiac events: an individual patient data meta-analysis. *J Am Coll Cardiol* 2011; 58: 522-9.
 35. Toussaint A, Weiss E, Khoy-Ear L, Janny S, Cohen J, Delefosse D, et al. Prognostic Value of Preoperative Brain Natriuretic Peptide Serum Levels in Liver Transplantation. *Transplantation* 2016; 100: 819-24.
 36. Mandell MS, Kay J. High-sensitivity troponins in liver transplantation: how will they change our practice? *Transplantation* 2018; 102: 716-7.
 37. Dolgin NH, Martins PN, Movahedi B, Lapane KL, Anderson FA, Bozorgzadeh A. Functional status predicts postoperative mortality after liver transplantation. *Clin Transplant* 2016; 30: 1403-10.
 38. Serper M, Bittermann T, Rossi M, Goldberg DS, Thomasson AM, Olthoff KM, et al. Functional status, healthcare utilization, and the costs of liver transplantation. *Am J Transplant* 2018; 18: 1187-96.
 39. Lai JC, Sonnenday CJ, Tapper EB, Duarte-Rojo A, Dunn MA, Bernal W, et al. Frailty in liver transplantation: An expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. *Am J Transplant* 2019; 19: 1896-906.
 40. Maile MD, Jewell ES, Engoren MC. Timing of preoperative troponin elevations and postoperative mortality after noncardiac surgery. *Anesth Analg* 2016; 123: 135-40.